Skip to main content

Table 1 Study Characteristics and Pregnancy Rates

From: A retrospective analysis of incident pregnancy in phase 1 and 2a HIV-1 vaccine study participants does not support concern for adverse pregnancy or birth outcomes

Study

Study Treatment

Participating Countries 1

N females of reproductive potential

N participants reporting one or more pregnancies

Pregnancies (main study)

Pregnancies (Long-term followup)

Pregnancies (total)

rate main

rate ltfu

rate total

Study Reference

HIVNET 026

canarypox + protein

BR, HT, PE, TT

60

6

7

0

7

8.05

n/a

8.05

http://www.ncbi.nlm.nih.gov/pubmed/17693888

HVTN 039

canarypox

US

30

0

0

0

0

0.00

n/a

0.00

http://www.ncbi.nlm.nih.gov/pubmed/16136469

HVTN 040

VEE

ZA, BW, US

17

2

2

0

2

13.33

n/a

13.33

http://www.ncbi.nlm.nih.gov/pubmed/22914365

HVTN 041

protein

US

22

0

0

0

0

0.00

n/a

0.00

http://www.ncbi.nlm.nih.gov/pubmed/17049679

HVTN 042

canarypox + lipopeptide

US

73

7

8

0

8

4.49

n/a

4.49

http://www.ncbi.nlm.nih.gov/pubmed/25253665

HVTN 044

DNA

US

23

1

1

0

1

2.70

n/a

2.70

http://www.ncbi.nlm.nih.gov/pubmed/21940420

HVTN 045

DNA

US

20

2

2

0

2

10.00

n/a

10.00

http://www.ncbi.nlm.nih.gov/pubmed/16831092

HVTN 048

DNA

BW, US

15

3

3

0

3

14.29

n/a

14.29

http://www.ncbi.nlm.nih.gov/pubmed/18055072

HVTN 049

DNA + protein

US

45

2

2

0

2

3.77

n/a

3.77

http://www.ncbi.nlm.nih.gov/pubmed/21451004

HVTN 050

Ad5

BR, DR, HT, MW, PE, PR, ZA, TH, US

162

20

5

21

26

3.14

3.48

3.41

http://www.ncbi.nlm.nih.gov/pubmed/20854108

HVTN 052

DNA

US

76

1

1

0

1

1.61

n/a

1.61

NCT00071851

HVTN 054

Ad5

US

21

0

0

0

0

0.00

n/a

0.00

http://www.ncbi.nlm.nih.gov/pubmed/21048953

HVTN 055

FPV + MVA

BR, US

74

2

2

0

2

2.60

n/a

2.60

http://www.ncbi.nlm.nih.gov/pubmed/21216311

HVTN 056

peptide

US

35

1

1

0

1

2.27

n/a

2.27

http://www.ncbi.nlm.nih.gov/pubmed/18996425

HVTN 057

DNA + Ad5 boost

US

30

0

0

0

0

0.00

n/a

0.00

NCT00091416

HVTN 059

VEE

BW, ZA, US

37

3

3

0

3

8.57

n/a

8.57

http://www.ncbi.nlm.nih.gov/pubmed/22914365

HVTN 060

DNA + IL12 DNA + peptide

TH, US

69

3

3

0

3

4.11

n/a

4.11

http://www.ncbi.nlm.nih.gov/pubmed/22242162

HVTN 063

DNA + IL12 DNA + IL15 DNA

BR, US

53

0

0

0

0

0.00

n/a

0.00

http://www.ncbi.nlm.nih.gov/pubmed/22242162

HVTN 064

peptide

US

28

1

1

0

1

3.70

n/a

3.70

http://www.ncbi.nlm.nih.gov/pubmed/19786145

HVTN 065

DNA + MVA

US

69

2

2

0

2

2.86

n/a

2.86

http://www.ncbi.nlm.nih.gov/pubmed/21282192

HVTN 067

DNA + MVA

US

15

0

0

0

0

0.00

n/a

0.00

http://www.ncbi.nlm.nih.gov/pubmed/22398243

HVTN 068

DNA + Ad5

US

30

0

0

0

0

0.00

n/a

0.00

http://www.ncbi.nlm.nih.gov/pubmed/26908875

HVTN 069

DNA + Ad5

PE, US

37

5

1

5

6

2.70

6.17

5.08

http://www.ncbi.nlm.nih.gov/pubmed/21931737

HVTN 070

DNA + IL12 DNA

US

59

4

4

0

4

7.27

n/a

7.27

http://www.ncbi.nlm.nih.gov/pubmed/23840043

HVTN 071

Ad5

US

21

1

1

0

1

4.76

0.00

1.09

http://www.ncbi.nlm.nih.gov/pubmed/23151505

HVTN 072

DNA + Ad5 + Ad35

US

4

0

0

0

0

0.00

0.00

0.00

NCT00472719

HVTN 073/E

DNA + MVA + protein

ZA, US

22

2

3

0

3

5.45

0.00

5.00

http://www.ncbi.nlm.nih.gov/pubmed/27098021

HVTN 076

DNA + Ad5

US

6

0

0

0

0

0.00

0.00

0.00

NCT00955006

HVTN 077

DNA + Ad5 + Ad35

US

81

5

1

6

7

1.30

2.10

1.93

http://www.ncbi.nlm.nih.gov/pubmed/26587311

HVTN 078

attenuated vaccinia + Ad5

CH

57

1

1

0

1

1.45

n/a

1.45

http://www.ncbi.nlm.nih.gov/pubmed/25271627

HVTN 080

DNA + IL12 DNA

US

27

0

0

0

0

0.00

n/a

0.00

http://www.ncbi.nlm.nih.gov/pubmed/23840043

HVTN 082

DNA + Ad5

US

8

0

0

0

0

0.00

0.00

0.00

NCT01054872

HVTN 083

Ad5

US

78

4

1

4

5

1.75

1.20

1.28

http://www.ncbi.nlm.nih.gov/pubmed/26475930

HVTN 084

Ad5

BR, PE, CH, US

82

16

0

19

19

0.00

5.18

4.70

http://www.ncbi.nlm.nih.gov/pubmed/31748227

HVTN 085

Ad5

US

37

4

0

4

4

0.00

2.35

2.11

NCT01479296

HVTN 086

DNA + MVA + protein

ZA

95

9

2

7

9

2.17

3.32

2.97

http://www.ncbi.nlm.nih.gov/pubmed/27583368

HVTN 087

DNA + IL12 DNA + VSV

US

35

1

0

1

1

0.00

3.85

1.49

https://www.ncbi.nlm.nih.gov/pubmed/30235286

HVTN 088

protein

US

13

2

2

0

2

7.41

n/a

7.41

https://www.ncbi.nlm.nih.gov/pubmed/30615119

HVTN 090

VSV

US

29

5

0

6

6

0.00

7.89

6.45

http://www.ncbi.nlm.nih.gov/pubmed/26199949

HVTN 092

DNA + attenuated vaccinia

CH, US

76

2

2

0

2

3.64

0.00

3.03

NCT01783977

HVTN 094

DNA + MVA

US

30

3

1

2

3

2.27

6.45

4.00

https://www.ncbi.nlm.nih.gov/pubmed/28727817

HVTN 096

DNA + attenuated vaccinia + protein

CH

49

10

3

9

12

4.35

3.95

4.04

https://www.ncbi.nlm.nih.gov/pubmed/31601541

HVTN 097

canarypox + protein

ZA

49

2

2

0

2

3.85

n/a

3.85

https://www.ncbi.nlm.nih.gov/pubmed/31534016

HVTN 098

DNA + IL12 DNA

US

40

1

1

0

1

1.75

n/a

1.75

NCT02431767

HVTN 100

canarypox + protein

ZA

109

4

4

0

4

1.82

n/a

1.82

https://www.ncbi.nlm.nih.gov/pubmed/29898870

HVTN 105

DNA + protein

US

48

0

0

0

0

0.00

n/a

0.00

https://www.ncbi.nlm.nih.gov/pubmed/31566579

HVTN 106

DNA + MVA

CH, US

44

2

2

0

2

4.08

n/a

4.08

NCT02296541

HVTN 110

Ad4 + protein

US

4

0

0

0

0

0.00

n/a

0.00

NCT02771730

HVTN 111

DNA + protein

ZA, TZ, ZM

65

1

1

0

1

1.59

n/a

1.59

https://www.ncbi.nlm.nih.gov/pubmed/31900486

HVTN 112

DNA + VSV

US

5

0

0

0

0

0.00

n/a

0.00

NCT02654080

HVTN 203

canarypox + protein

US

81

4

5

0

5

4.24

n/a

4.24

http://www.ncbi.nlm.nih.gov/pubmed/17106277

HVTN 204

DNA + Ad5

BR, HT, JM, ZA, US

254

18

18

0

18

3.01

n/a

3.01

http://www.ncbi.nlm.nih.gov/pubmed/21857901

HVTN 205

DNA + MVA

PE, US

124

10

5

6

11

4.17

2.80

3.29

http://www.ncbi.nlm.nih.gov/pubmed/24403557

Total

  

2673

172

103

90

193

3.09

3.22

3.15

 
  1. 1 – ISO 3166 codes for countries and territories: BR Brazil, BW Botswana, CH Switzerland, DO Dominican Republic, HT Haïti, JM Jamaica, PE Peru, PR Puerto Rico, MW Malawi, TH Thailand, TT Trinidad and Tobago, TZ Tanzania, US United States, ZA South Africa, ZM Zambia